Download by
Scanning QR Code
No Data
US Stock MarketDetailed Quotes
ACRX AcelRx Pharmaceuticals
Watchlist
0.5735
+0.0235+4.27% Close 10/03 16:00 ET
0.5601-0.0134-2.34%
Post 16:16 ET
0.5898High0.5400Low424.23KVolume
0.5567Open0.5500Pre Close238.66KTurnover3.37%Turnover RatioLossP/E (TTM)9.37MMarket Cap4.788052wk High0.10P/E (Static)16.34MShares0.540052wk Low0.90P/B7.22MFloat Cap272.8000Historical High--Dividend TTM12.59MShs Float0.5400Historical Low--Div YieldTTM9.06%Amplitude0.5620Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About AcelRx Pharmaceuticals Company
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
News
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
Investigational Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) allows AcelRx to begin pivotal study of Niyad Single registration study with pre-agreed upon endpoints planned to
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
UpgradesFor Invitation Homes Inc (NYSE:INVH), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the second quarter, Invitation Homes had an EPS of $0.44, compared to year-a
Alliance Global Partners Initiates Coverage On AcelRx Pharmaceuticals With Buy Rating, Announces Price Target of $4.25
Alliance Global Partners analyst James Molloy initiates coverage on AcelRx Pharmaceuticals (NASDAQ:ACRX) with a Buy rating and announces Price Target of $4.25.